MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1352458519852093

Медицинская библиотека · Multiple sclerosis (Houndmills, Basingstoke, England) · 2019

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

Brown J William L, Prados Carrasco Ferran, Eshaghi Arman, Sudre Carole H, Button Tom, Pardini Matteo, Samson Rebecca S, Ourselin Sebastien, Wheeler-Kingshott Claudia Am Gandini, Jones Joanne L, Coles Alasdair J, Chard Declan T

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In multiple sclerosis (MS), disease effects on magnetisation transfer ratio (MTR) increase towards the ventricles. This periventricular gradient is evident shortly after first symptoms and is independent of white matter lesions.

OBJECTIVE

To explore if alemtuzumab, a peripherally acting disease-modifying treatment, modifies the gradient's evolution, and whether baseline gradients predict on-treatment relapses.

METHODS

Thirty-four people with relapsing-remitting MS underwent annual magnetic resonance imaging (MRI) scanning (19 receiving alemtuzumab (four scans each), 15 untreated (three scans each)). The normal-appearing white matter was segmented into concentric bands. Gradients were measured over the three bands nearest the ventricles. Mixed-effects models adjusted for age, gender, relapse rate, lesion number and brain parenchymal fraction compared the groups' baseline gradients and evolution.

RESULTS

Untreated, the mean MTR gradient increased (+0.030 pu/band/year) but decreased following alemtuzumab (-0.045 pu/band/year, p = 0.037). Within the alemtuzumab group, there were no significant differences in baseline lesion number (p = 0.568) nor brain parenchymal fraction (p = 0.187) between those who relapsed within 4 years (n = 4) and those who did not (n = 15). However, the baseline gradient was significantly different (p = 0.020).

CONCLUSION

Untreated, abnormal periventricular gradients worsen with time, but appear reversible with peripheral immunotherapy. Baseline gradients - but not lesion loads or brain volumes - may predict on-treatment relapses. Larger confirmatory studies are required.

Для цитирования: Brown J William L, Prados Carrasco Ferran, Eshaghi Arman, Sudre Carole H, Button Tom, Pardini Matteo, Samson Rebecca S, Ourselin Sebastien, Wheeler-Kingshott Claudia Am Gandini, Jones Joanne L, Coles Alasdair J, Chard Declan T. Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019. DOI: 10.1177/1352458519852093.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.